Vaccine Process Development and Manufacturing
Ambr® 15 Cell Culture is a high throughput, automated bioreactor system for 24 or 48 parallel cultivations at the 10 –15 mL microbioreactor scale.
Vaccination is one of the great inventions of all time. Vaccines have saved countless lives and improved the health of people all over the world.
Sartorius technology supports the production of traditional vaccines and emerging technologies such as recombinant vaccines. This is helping the industry to address both global endemic diseases and less predictable, but potentially devastating, localized outbreaks.
More than ever, people around the world need access to vaccines produced to rigorous standards of quality but at low cost. Flexible production facilities are needed that will allow capacity to be modulated easily. Increasingly vaccine manufacturers are seeking to construct and operate these facilities in locations across the globe to shorten delivery times and cold chain supply networks.
Vaccine Development for SARS-CoV-2 Coronavirus Causing COVID-19 Pandemic
Solutions to Fight the Coronavirus Outbreak
The current Coronavirus outbreak is creating serious health and economic impact in the entire world as it spreads at unprecedented speed. Many private and public companies, and funding organizations are putting a significant amount of effort to develop a vaccine that could stop the spreading of the virus, thus saving thousands of lives. In such times speed is of essence and vaccine manufacturers will be looking for agile and responsive partners like Sartorius.
Development and Manufacturing of Viral Vectors
Learn more about our single-use technologies and associated services to address the process development and production of viral vectors.
Discover Latest Results Obtained for Coronaviridae Quantification
Download the poster on rapid total viral particle quantification for viral families.
Virus Counter for Rapid Virus Quantification
A unique automated platform for real-time tracking of viral particles and quantification of total intact virus particles.
Implementing Process-Scale Adenovirus Purification
Read how single-use platform accelerate vaccine development and manufacturing.
Adenovirus Downstream Process Intensification at GSK
Learn how GSK implemented a membrane adsorber to intensify adenovirus purification.
Discover the ABL Europe’s New Viral Vector
Production Facility
Production Facility
Recommendation for Vaccine Manufacturers Considering Implementing Production Solutions
Amélie Boulais, Vaccine Platform Marketing Manager at Sartorius Stedim Biotech
“Customers should not hesitate to explore innovative new processing solutions that can have an enormous impact on the productivity of the final process. Early stage development scientists now have access to bioprocessing technologies that can then be scaled-up into cGMP production. There are many good high-throughput screening tools and scale-down models for process development these days. Sartorius Process Development Consultants can help you develop an overall strategy for the design and implementation of your new vaccine process and our application scientists will assist you in optimizing individual steps.”
Vaccine Development Platforms
As the industry is racing to develop a vaccine, we want to ensure access to relevant technical information in a convenient and straightforward format. Our interactive process flow-chart provides an overview of various vaccine platforms that could be used for creating a COVID-19 vaccine. Explore our generic processes for viral vector vaccines, attenuated and inactivated viral vaccines, click on each step to reveal the specific challenges, and discover how Sartorius solutions meet those needs.
Vaccine Related Publications
ABL Europe’s New Production Facility for the GMP Manufacture of Viral Vectors
PDF | 7.6 MB
Accelerated Development, Manufacturing and Monitoring of Viral Vectors
PDF | 3.5 MB
Discover further Sartorius Platforms for Biomanufacturing
Scalable Single-Use Toolbox for Your mAb Process Platform
Regenerative Medicine
